Company Incannex Healthcare Inc.

IXHL

US45333F1093

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Annual profits - Rate of surprise

Sector Alternative Medicine

Market Closed - Nasdaq Other stock markets 04:30:01 2024-07-12 pm EDT			5-day change	1st Jan Change
2.746 ^USD	-0.34%		-0.77%	-40.83%

May. 30	Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	CI
May. 15	Incannex Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI

Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Companyâs diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.

Number of employees: 3

Managers	Title	Age	Since
Joel Latham CEO	Chief Executive Officer	35	23-07-04
Joseph Swan DFI	Director of Finance/CFO	33	23-07-04
Parisa Asvadi CTO	Chief Tech/Sci/R&D Officer	-	-
Rosemarie Walsh CTO	Chief Tech/Sci/R&D Officer	-	20-04-30
Mark Bleackley CTO	Chief Tech/Sci/R&D Officer	-	-
Lekhram Changoer CTO	Chief Tech/Sci/R&D Officer	58	23-07-04
Brad Dilkes IRC	Investor Relations Contact	-	-
Kalani Scarrott AUD	Comptroller/Controller/Auditor	-	-

Members of the board	Title	Age	Since
Robert Clark BRD	Director/Board Member	64	Oct. 31
George Anastassov BRD	Director/Board Member	60	Oct. 31
Troy Valentine CHM	Chairman	50	Oct. 31
Peter Widdows BRD	Director/Board Member	58	Oct. 31
Joel Latham CEO	Chief Executive Officer	35	23-07-04

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	15,873,113	12,038,568 ( 75.84 %)	0	75.84 %

Name	Equities	%	Valuation
Joel Latham 9.938 %	1,577,485	9.938 %	5 M $
Troy Valentine 6.530 %	1,036,512	6.530 %	3 M $
George Anastassov 4.849 %	769,721	4.849 %	2 M $
Lekhram Changoer 4.029 %	639,549	4.029 %	2 M $
Tidal Investments LLC 2.667 %	423,410	2.667 %	1 M $
ETF Managers Group LLC 1.982 %	314,609	1.982 %	924 950 $
Peter Widdows 1.706 %	270,847	1.706 %	796 290 $
Robert Clark 0.6300 %	100,000	0.6300 %	294 000 $
HRT Financial LLC 0.5227 %	82,972	0.5227 %	243 938 $
AdvisorShares Investments LLC 0.3208 %	50,915	0.3208 %	149 690 $

Incannex Healthcare, Inc.

8 Century Circuit Suite 105

2153, Norwest

+61 4 2570 3805

http://www.incannex.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Alternative Medicine

	1st Jan change	Capi.
INCANNEX HEALTHCARE INC.	-40.83%	43.58M
DONG-E-E-JIAO CO.,LTD.	+12.92%	4.95B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-32.29%	3.6B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-4.28%	3.03B
TASLY PHARMACEUTICAL GROUP CO., LTD	-24.21%	2.66B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-8.82%	2.34B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+39.33%	1.85B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+40.81%	1.45B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-14.27%	1.41B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK	+41.90%	1.38B

Alternative Medicine